United Therapeutics Shares Drop 2.8% as $540M Volume Ranks 182nd Amid Bullish Developments

On September 4, 2025, United Therapeutics (UTHR) closed at $380.47, down 2.80% with a trading volume of $540 million, ranking 182nd in market activity. The stock’s decline contrasts with recent bullish developments, including a revised $560 price target from UBS following successful Phase 3 TETON-2 trial results for its drug Tyvaso. The trial demonstrated significant improvements in forced vital capacity for idiopathic pulmonary fibrosis (IPF) patients, positioning Tyvaso as a potential standard of care in a $4 billion market dominated by suboptimal therapies.

UBS highlighted Tyvaso’s commercial potential, raising its peak sales forecast to $3.3 billion and identifying key catalysts, including detailed TETON-2 data presentation at the ERS Congress on September 28 and the TETON-1 trial readout in early 2026. The firm also emphasized United Therapeutics’ strong financial metrics, including an 89% gross margin and a 14.4 P/E ratio, despite the stock’s recent pullback. Meanwhile, the company expanded its collaboration with MannKind Corporation to develop a second dry powder inhalation therapy, building on the success of Tyvaso DPI, the first FDA-approved treatment in its class for pulmonary hypertension.

Backtest results indicate that United Therapeutics’ stock has historically responded positively to clinical milestones and partnership advancements. The TETON-2 success aligns with past patterns where regulatory and market access progress drove sustained outperformance. However, near-term volatility may persist as investors await further data and regulatory clarity, particularly given the competitive landscape and high unmet need in the IPF market.